Apelin-13 Pyroglutamate: Why One Name Covers Two Molecules

Order apelin-13 from two vendors and you may receive two different compounds with the same name on the label. The reason is apelin-13 pyroglutamate: the N-terminal glutamine of this thirteen-residue peptide closes into a ring on its own, sheds ammonia and leaves a molecule 17 daltons lighter. For a lab buying this material in quantity, that conversion decides what goes on the purchase order, what the certificate should show and how the vials are stored once they arrive. This guide covers each of those points from the receiving bench’s point of view.

One chain, two catalogue entries

The underlying sequence is the same in both products: Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe, which corresponds to the last thirteen residues of the apelin precursor. What differs is the first residue.

Both are legitimate research reagents, and the literature uses both. In receptor work, each is reported to act at the apelin receptor (APJ), a class A G protein-coupled receptor, and the cyclised version is frequently described as the predominant endogenous form. That is exactly why a study design has to name one of them. A dataset generated with a mixture of unknown proportion is hard to compare with anything published.

Where the 17 daltons go

The side-chain amide of an N-terminal glutamine sits close to the free alpha-amine of the same residue. Under the right conditions the amine attacks the side-chain carbonyl, a five-membered lactam forms, and the displaced nitrogen leaves as ammonia (NH3, 17.03 Da). The product is pyroglutamic acid, often abbreviated pGlu, Pyr or pE.

A few features of this reaction matter in practice:

• It needs no enzyme. Glutaminyl cyclase speeds it up in biological systems, but a peptide solution sitting on a bench will convert without any help.
• Conditions set the rate. Temperature, pH and buffer composition all influence how quickly it proceeds, and phosphate is among the buffers reported to accelerate it.
• It runs one way. Once cyclised, the N-terminus has no free primary amine left, so the product does not revert and is chemically quieter than the starting peptide.
• It is not a synthesis fault. Any sequence that starts with glutamine carries this tendency. Apelin-13 is simply the most familiar example among research peptides.

The loss of that free amine also changes the charge picture. The open form carries an extra positive charge at acidic pH, so the two species behave slightly differently on a column, which is what makes the conversion measurable.

Reading an apelin-13 pyroglutamate result on HPLC and MS

A good certificate for either form lines up three fields: the name, the measured mass and the chromatogram. When they disagree, trust the mass. A heading that says apelin-13 above a measured mass near 1533.8 describes the cyclised peptide, whatever the template text says.

On a reversed-phase trace, partial conversion shows up as a pair of closely eluting peaks. Collect the mass across each and you will find them 17 daltons apart. That pairing is a genuine and very common result for this compound, not a column artefact or an unrelated contaminant, and the ratio between the two areas is the number worth recording.

In electrospray, apelin-13 is basic enough to ionise well in positive mode. The doubly and triply protonated ions dominate, so the 17 dalton gap appears as a shift of roughly 8.5 m/z in the 2+ state and about 5.7 m/z in the 3+ state. Deconvoluting to a neutral mass makes the comparison far easier to read than scanning raw charge states.

Because the peptide carries two arginines, a lysine and a histidine with no acidic side chains, it tails on silica-based C18 packings unless an ion-pairing agent is present. Trifluoroacetic acid in the mobile phase is the usual fix, and a report run without it may show a peak shape that says more about the method than the material.

The methionine at position 11

Apelin-13 has a second built-in liability. Methionine oxidises to the sulfoxide, adding 16 daltons, and it can do so during handling and storage rather than during synthesis. On most peptides that is a routine impurity. Here it overlaps with the cyclisation arithmetic.

Consider a molecule that has both cyclised and oxidised. It has lost 17 and gained 16, so its mass sits just one dalton below the unmodified open form. On a low-resolution instrument that species can hide inside the parent’s isotope envelope. Two approaches deal with it: high-resolution mass measurement, or a gradient shallow enough that the oxidised species separates before it reaches the detector. The second is usually the practical route for a QC lab.

Keeping the ratio stable across a multi-vial order

For a lab drawing on the same order over several months, the proportion of each form is the thing most likely to drift, and it drifts fastest in solution. A few habits keep it under control:

1. Log the stated form and the certificate ratio for the lot when the shipment is received, and match every vial to that record.
2. Keep unopened vials lyophilised, sealed, cold and dark until needed. The dry cake converts far more slowly than any solution.
3. Prepare analytical solutions close to the time of use rather than holding stock solutions for weeks.
4. Where a solution must be held, note the buffer and the storage temperature, and re-check the ratio before relying on it.
5. If a later analysis shows more of the cyclised form than the certificate did, treat that as a storage record to investigate rather than a sign the original analysis was wrong.

A material certified as the open peptide will not stay that way indefinitely once dissolved. That is an argument for lyophilised storage and prompt preparation, not for distrusting the paperwork.

Longer apelin fragments are different compounds

The apelin precursor gives rise to several fragments, and the number in each name is its residue count. The 17-residue and 36-residue versions reach back further along the precursor, carry larger masses and cannot be substituted for apelin-13 or compared against its certificate. Because the family shares a C-terminal phenylalanine, a C-terminal fragment ion in a spectrum does not by itself tell the members apart. Intact mass does.

What to write on the purchase order

For a volume purchase, put the identity requirement in writing so every reorder is checked against the same standard:

• The form, stated explicitly: apelin-13 with a free N-terminus, or [Pyr1]apelin-13.
• The full sequence, including the N-terminal residue as Gln or pGlu.
• The expected mass: about 1550.8 Da average for the open form, about 1533.8 Da for the cyclised form.
• A minimum HPLC purity, and a request that any second peak 17 daltons away be reported as a percentage.
• Where possible, a single lot for the whole order, so every vial shares one certificate.

Bulk Peptides does not list apelin-13 in its current range, so treat this as a general reference for specifying and receiving it from any source. The same logic applies to any peptide that begins with glutamine.

This article is an analytical reference for laboratory researchers. Apelin-13 and related peptides are discussed only as in-vitro research materials, not for use in people or animals.